General Announcement-Press Release - iXB 401 Achieves 20x Higher Bioavailability Than Rybelsus in Preclinical Study
General Announcement-Minutes of Extraordinary General Meeting Held on 17 October 2024
General Announcement-Minutes of Annual General Meeting Held on 17 October 2024
General Announcement-Formation of the Audit and Risk Committee and Reconstitution of the Board Committees
General Announcement-Press Release - iX Biopharma Appoints Dr. Brian Kennedy as New Scientific Advisor
Change - Announcement of Cessation-Retirement of Independent Director
Financial Statements and Related Announcement-Auditor's Comments of Accounts
General Announcement-Press Release - Business and Drug Development Updates - Wafermine and iXB 401
General Announcement-Press Release - New Study Demonstrates that SL-NAD+ Delivers NAD+ into Cells
Financial Statements and Related Announcement-Full Yearly Results
General Announcement-Press Release - New Study Highlights CBD Wafer's Potential in Kidney Failure Patients
Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)-Changes in Interest by Substantial Shareholder - Anson Properties Pte. Ltd.
Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer-Disclosure of Interest/ Changes in Interest of Director - Albert Ho Shing Tung
Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer-Disclosure of Interest/ Changes in Interest of Director - Eddy Lee Yip Hang
Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer-Disclosure of Interest/ Changes in Interest of Director - Albert Ho Shing Tung
Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer-Disclosure of Interest/ Changes in Interest of Director - Eddy Lee Yip Hang
REPL-General Announcement-Issue and Listing of the Rights Shares and the Warrants
General Announcement-Issue and Listing of the Rights Shares and the Warrants
No Data